BridgeBio Pharma Inc. (BBIO) Misses Q2 EPS by 20c
Tweet
Share
E-mailGet Alerts BBIO Hot Sheet
Join SI Premium – FREE
BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q2 EPS of ($0.95), $0.20 worse than the analyst estimate of ($0.75). Revenue for the quarter came in at $110.56 million versus the consensus estimate of $99.72 million.
For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Cheap but fundamentally challenged': BofA reinstates Adobe at Underperform
- Digi Power X Provides Operations and Financial Update
- Rosenblatt Reiterates Buy Rating on Walt Disney (DIS)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
